Matt Halpert 1 source tracked
Cancer immunologist and co-founder of Diakonos Oncology, developing dendritic cell–based immunotherapies for cancer.
About Matt Halpert →
Matt Halpert is a cancer immunologist known for his work on dendritic cell–based cancer immunotherapy. He earned his Ph.D. in Microbiology and Immunology from the University of Alabama at Birmingham and spent roughly a decade as a cancer immunology researcher at Baylor College of Medicine, where his work included findings on CTLA-4 production by dendritic cells. He is a co-founder of Diakonos Oncology and is associated with the Immunocine Cancer Center, where he has helped develop dendritic cell therapies that have entered FDA clinical trials, including a Fast Track trial in glioblastoma.
-
Guest recommendation In a protocol
When tumor tissue is biopsied or resected, cryopreserve a portion rather than sending all of it to pathology in formaldehyde or paraffin, which destroys its usefulness for immunotherapy manufacturing.
“You don't want it to be dunked in formaldehyde or paraffin or fixatives, that actually destroys it.
TU▶ 40:00DosageCoordinate with surgeon in advance to save a portion of fresh tumor via cryopreservation before pathology fixation.Certaintyexplicitrecommendation -
Guest recommendation In a protocol
Personalized double-loaded dendritic cell vaccine therapy from the patient's own tumor tissue, used to train the immune system to recognize and attack cancer; available via FDA trials (glioblastoma, pancreatic ductal adenocarcinoma, refractory melanoma) and via Immunocine clinics in Cancun and Cabo for other cases.
“Turn your immune system on, get it in the game.
TU▶ 1:00:00DosageBiopsy tumor tissue (cryopreserved, not formalin-fixed), manufacture personalized DC vaccine, administer via image-guided injection near functional draining lymph nodes; three or more shots depending on protocol.CaveatsNot a guarantee of cure; not ideal if patient has weeks to live, uncontrolled systemic inflammation, or no residual tumor to sample; FDA trials limited to specific cancers in US.Certaintyexplicitstrong endorsement -
Guest recommendation In a protocol
Pursue dendritic cell vaccine therapy earlier in the cancer course (during stable disease, remission, or alongside standard care) rather than waiting until end-of-road relapse, since the immune response needs time to develop.
“The optimal time to do a treatment like this is not... let's wait till the last minute.
TU▶ 43:00CaveatsNot appropriate when prognosis is only weeks; may need to buy time with conventional care first.Certaintyexplicitrecommendation -
Guest recommendation In a protocol
Cryopreserve a sample of your tumor at the time of initial biopsy/surgery as a safeguard so personalized dendritic cell vaccine can be made later if conventional therapy fails or cancer relapses.
“Save some cancer.
TU▶ 1:05:00DosageRequest a kit from Immunocine Preserve; have surgeon place tumor tissue directly in provided solution tubes (avoid formaldehyde/paraffin fixatives) and ship overnight via FedEx.CaveatsMust be arranged before surgery/biopsy so the sample is not sent to pathology in fixative.Certaintyexplicitstrong endorsement -
Guest recommendation In a protocol
Apply at immunocine.com for a free case review to determine whether dendritic cell vaccine therapy is appropriate; separate immunocinepreserve.com for tumor cryopreservation logistics.
“We don't really charge for... give us a shot. Send us your record, send us your scans.
TU▶ 1:06:00DosageSubmit records and scans for free review; set up private call if candidate.CaveatsInclusion criteria apply; not everyone is accepted.Certaintyexplicitrecommendation -
Guest recommendation In a protocol
Lower systemic inflammatory markers (LDH, CRP, ESR, RDW) before beginning dendritic cell vaccine therapy so the activated immune response can follow a gradient to the tumor rather than being lost in system-wide inflammation.
“Try to get your inflammation as under control as you can.
TU▶ 1:04:00DosageAddress markers such as LDH, CRP, ESR, RDW prior to treatment.CaveatsMust still allow a localized inflammatory response at the tumor site.Certaintyexplicitrecommendation